Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to UY27569ApriorityCriticalpatent/UY27569A1/en
Publication of UY27569A1publicationCriticalpatent/UY27569A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una combinación de una forma cristalina de 6-((2,2-difenitel)amino)-9-(N-5 etil-B-D-ribofuranosiluronamida)-N-(2-(N'-(1-(2-piridil)-4-piperidil)ureido)etil)-9H-purin-2-carboxamida y una sal de tiotropio. Tal combinación es útil en el tratamiento de enfermedades respiratorias tales como enfermedad pulmonar obstructiva crónica.The present invention relates to a combination of a crystalline form of 6 - ((2,2-diphenyle) amino) -9- (N-5-ethyl-BD-ribofuranosyluronamide) -N- (2- (N '- (1 - (2-Pyridyl) -4-piperidyl) ureido) ethyl) -9H-purin-2-carboxamide and a tiotropium salt. Such a combination is useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease.
UY27569A2002-12-052002-12-05
COMBINATION OF A FORM OF CRYSTAL DRUG AND A TIOTROPIO SALT
UY27569A1
(en)
New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease